CARA Cara Therapeutics Inc

Cara Therapeutics to Announce First Quarter 2024 Financial Results on May 13, 2024

Cara Therapeutics to Announce First Quarter 2024 Financial Results on May 13, 2024

STAMFORD, Conn., May 06, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will report first quarter 2024 financial results on Monday, May 13, 2024, after the U.S. markets close. The press release will be available under “Press Releases” in the Investors section of the Company’s website at .

About Cara Therapeutics

Cara Therapeutics is a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company is developing an oral formulation of difelikefalin, a selective, peripherally acting, non-scheduled kappa opioid receptor agonist, for the treatment of chronic pruritus associated with notalgia paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back for which there are no FDA-approved therapies. The Company is conducting a Phase 2/3 clinical program in NP with topline results of the dose-finding portion expected in the third quarter of 2024. Cara Therapeutics also developed an IV formulation of difelikefalin, which is approved in the United States, EU, and multiple other countries for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide. For more information, visit and follow the company on , and .

MEDIA CONTACT:

Annie Spinetta

6 Degrees

973-768-2170

INVESTOR CONTACT:

Iris Francesconi, Ph.D.

Cara Therapeutics

203-406-3700



EN
06/05/2024

Underlying

CARACara Therapeutics Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cara Therapeutics Inc

 PRESS RELEASE
Free
CARA Cara Therapeuti...

Cara Therapeutics Reports First Quarter 2024 Financial Results

Cara Therapeutics Reports First Quarter 2024 Financial Results Topline efficacy and safety results from KOURAGE 1 Part A portion of notalgia paresthetica (NP) pivotal program now expected by the end of 2Q24 STAMFORD, Conn., May 13, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operational highlights for the first quarter ended March 31, 2024. “Our notalgia paresthetica (NP) pivotal clini...

May 13, 2024 1 EN
 PRESS RELEASE
Free
CARA Cara Therapeuti...

Cara Therapeutics to Announce First Quarter 2024 Financial Results on ...

Cara Therapeutics to Announce First Quarter 2024 Financial Results on May 13, 2024 STAMFORD, Conn., May 06, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will report first quarter 2024 financial results on Monday, May 13, 2024, after the U.S. markets close. The press release will be available under “Press Releases” in the Investors section of the Company’s website at . About Cara Therapeutics Cara Therapeu...

May 6, 2024 1 EN
 PRESS RELEASE
Free
CARA Cara Therapeuti...

Cara Therapeutics to Present at the 23rd Annual Needham Virtual Health...

Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference STAMFORD, Conn., April 02, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive Officer, will present at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 8:40 a.m. EDT. A webcast of the presentation can be accessed under "Events & Presentations" in the ...

April 2, 2024 1 EN
 PRESS RELEASE
Free
CARA Cara Therapeuti...

Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event...

Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024 STAMFORD, Conn., March 07, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a virtual key opinion leader (KOL) event titled “Meet the NP Experts” on Wednesday, March 27, 2024, at 10:00 a.m. EDT. The event will feature a panel of leaders in the field of neuropathic pruritus who will discuss the epidemio...

March 7, 2024 1 EN
 PRESS RELEASE
Free
CARA Cara Therapeuti...

Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financia...

Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results –Announced prioritization of clinical programs to focus on late-stage development of oral difelikefalin for notalgia paresthetica (NP)– –Completed enrollment of KOURAGE 1 Part A portion of NP pivotal program ahead of schedule; topline efficacy and safety results now expected in 3Q24– –Extended cash runway into 2026 with clinical prioritization strategy and reduction in force– –Conference call today at 4:30 p.m. EST– STAMFORD, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA),...

March 4, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch